BCL2 and MCL1 inhibitors for hematologic malignancies
AW Roberts, AH Wei… - Blood, The Journal of the …, 2021 - ashpublications.org
BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …
hematologic cancers and play important roles in their biology either through dysregulation or …
[HTML][HTML] MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
A Bolomsky, M Vogler, MC Köse, CA Heckman… - Journal of hematology & …, 2020 - Springer
Cell death escape is one of the most prominent features of tumor cells and closely linked to
the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic …
the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic …
[HTML][HTML] Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells
BM Stevens, CL Jones, DA Pollyea, R Culp-Hill… - Nature cancer, 2020 - nature.com
Venetoclax with azacitidine (ven/aza) has emerged as a promising treatment regimen for
acute myeloid leukemia (AML), with a high percentage of clinical remissions in newly …
acute myeloid leukemia (AML), with a high percentage of clinical remissions in newly …
Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia
S Pei, DA Pollyea, A Gustafson, BM Stevens… - Cancer discovery, 2020 - AACR
Venetoclax-based therapy can induce responses in approximately 70% of older previously
untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well …
untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well …
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
EM Cherry, D Abbott, M Amaya, C McMahon… - Blood …, 2021 - ashpublications.org
Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …
Implementing a functional precision medicine tumor board for acute myeloid leukemia
We generated ex vivo drug-response and multiomics profiling data for a prospective series
of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision …
of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision …
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
Deregulation of the BCL2 gene family plays an important role in the pathogenesis of acute
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …
myeloid leukemia (AML). A BCL2 inhibitor, venetoclax, has received approval from the US …
Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine/venetoclax
The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently
transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically …
transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically …
[HTML][HTML] Venetoclax resistance: mechanistic insights and future strategies
F Ong, K Kim, MY Konopleva - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …